• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PharmaNet, McGill to develop Canadian translational research facility

PharmaNet, McGill to develop Canadian translational research facility

September 15, 2011
CenterWatch Staff

PharmaNet Development Group, the US-based clinical development services provider acquired by inVentiv Health, has teamed up with a Canadian research institute to set up what the company says will be the country’s first in-hospital translational medicine unit for phase I-IIa clinical trials, according to PharmaTimes.

PharmaNet’s local subsidiary, PharmaNet Canada, has signed a letter of intent with The Research Institute of McGill University Health Centre (RI MUHC) in Montreal for a joint venture to establish, manage and operate the facility at the Montreal General Hospital.

The translational medicine unit, which PharmaNet says will “transform” the way pivotal proof-of-concept studies are conducted, is expected to start operations in 2012. According to Riaz Bandali, president, early stage development for PharmaNet, the initiative “aligns PharmaNet’s and RI MUHC’s objectives of optimally developing innovative therapeutics for patients in need.”

Pharmaceutical and biopharmaceutical companies using the facility will have access to state-of-the-art capabilities, specialized scientific knowledge, a broad range of patients, and “unsurpassed” medical and clinical development expertise within a safe hospital environment, Bandali added.

RI MUHC director Dr Vassilios Papadopoulos cited the Institute’s medical and scientific leadership in the understanding of diseases such as cancer, respiratory illness and cardiovascular failure.  

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing